

Alessandro Ottaiano

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3784801/publications.pdf>

Version: 2024-02-01

107
papers

2,364
citations

236925

25
h-index

243625

44
g-index

110
all docs

110
docs citations

110
times ranked

3317
citing authors

#	ARTICLE	IF	CITATIONS
1	Metastatic colorectal cancer and type 2 diabetes: prognostic and genetic interactions. <i>Molecular Oncology</i> , 2022, 16, 319-332.	4.6	13
2	Clinical and Molecular Characteristics of Rare Malignant Tumors of Colon and Rectum. <i>Biology</i> , 2022, 11, 267.	2.8	8
3	Contrast MR-Based Radiomics and Machine Learning Analysis to Assess Clinical Outcomes following Liver Resection in Colorectal Liver Metastases: A Preliminary Study. <i>Cancers</i> , 2022, 14, 1110.	3.7	27
4	EOB-MR Based Radiomics Analysis to Assess Clinical Outcomes following Liver Resection in Colorectal Liver Metastases. <i>Cancers</i> , 2022, 14, 1239.	3.7	23
5	Radiomics textural features by MR imaging to assess clinical outcomes following liver resection in colorectal liver metastases. <i>Radiologia Medica</i> , 2022, 127, 461-470.	7.7	49
6	Editorial: The Treatment of RAS or BRAF Mutated Metastatic Colorectal Cancer: Challenges and Perspectives. <i>Frontiers in Oncology</i> , 2022, 12, 852445.	2.8	1
7	Conventional, functional and radiomics assessment for intrahepatic cholangiocarcinoma. <i>Infectious Agents and Cancer</i> , 2022, 17, 13.	2.6	9
8	Initial tumour burden and hidden oligometastatic disease in phase 3 clinical trials. <i>Lancet Oncology</i> , 2022, 23, 452-454.	10.7	4
9	Magnetic Resonance Features of Liver Mucinous Colorectal Metastases: What the Radiologist Should Know. <i>Journal of Clinical Medicine</i> , 2022, 11, 2221.	2.4	13
10	Radiomics and Machine Learning Analysis Based on Magnetic Resonance Imaging in the Assessment of Colorectal Liver Metastases Growth Pattern. <i>Diagnostics</i> , 2022, 12, 1115.	2.6	20
11	VOSviewer-Based Bibliometric Network Analysis for Evaluating Research on Juvenile Primary Fibromyalgia Syndrome (JPFS). <i>Children</i> , 2022, 9, 637.	1.5	16
12	Radiomics and machine learning analysis based on magnetic resonance imaging in the assessment of liver mucinous colorectal metastases. <i>Radiologia Medica</i> , 2022, 127, 763-772.	7.7	38
13	Tumour Burden Reporting in Phase III Clinical Trials of Metastatic Lung, Breast, and Colorectal Cancers: A Systematic Review. <i>Cancers</i> , 2022, 14, 3262.	3.7	3
14	Aflibercept or bevacizumab in combination with FOLFIRI as second-line treatment of mRAS metastatic colorectal cancer patients: the ARBITRATION study protocol. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592198922.	3.2	7
15	COVID-19 Outbreak: The North versus South Epidemiologic Italian Paradigm. <i>Journal of Epidemiology and Global Health</i> , 2021, 11, 253.	2.9	4
16	Radiomics-Derived Data by Contrast Enhanced Magnetic Resonance in RAS Mutations Detection in Colorectal Liver Metastases. <i>Cancers</i> , 2021, 13, 453.	3.7	50
17	KRAS Mutational Regression Is Associated With Oligo-Metastatic Status and Good Prognosis in Metastatic Colorectal Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 632962.	2.8	9
18	The Role of microRNAs in Development of Colitis-Associated Colorectal Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3967.	4.1	25

#	ARTICLE	IF	CITATIONS
19	Is immunotherapy in the future of therapeutic management of sarcomas?. <i>Journal of Translational Medicine</i> , 2021, 19, 173.	4.4	18
20	Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: A Big and Intriguing Challenge Which May Be Resolved by Integrated Treatments Combining Locoregional and Systemic Therapies. <i>Cancers</i> , 2021, 13, 2371.	3.7	35
21	Poorly Differentiated Neuroendocrine Larynx Carcinoma: Clinical Features and miRNAs Signature—A New Goal for Early Diagnosis and Therapy?. <i>Journal of Clinical Medicine</i> , 2021, 10, 2019.	2.4	5
22	Prognostic Significance of CXCR4 in Colorectal Cancer: An Updated Meta-Analysis and Critical Appraisal. <i>Cancers</i> , 2021, 13, 3284.	3.7	8
23	Malignant Sinonasal Tumors: Update on Histological and Clinical Management. <i>Current Oncology</i> , 2021, 28, 2420-2438.	2.2	19
24	Diagnostic evaluation and ablation treatments assessment in hepatocellular carcinoma. <i>Infectious Agents and Cancer</i> , 2021, 16, 53.	2.6	25
25	Translational Insights and New Therapeutic Perspectives in Head and Neck Tumors. <i>Biomedicines</i> , 2021, 9, 1045.	3.2	4
26	Prospective Evaluation of Radiotherapy-Induced Immunologic and Genetic Effects in Colorectal Cancer Oligo-Metastatic Patients with Lung-Limited Disease: The PRELUDE-1 Study. <i>Cancers</i> , 2021, 13, 4236.	3.7	8
27	Genetic regressive trajectories in colorectal cancer: A new hallmark of oligo-metastatic disease?. <i>Translational Oncology</i> , 2021, 14, 101131.	3.7	14
28	Bevacizumab-Induced Tumor Vasculature Normalization and Sequential Chemotherapy in Colorectal Cancer: An Interesting and Still Open Question. <i>Frontiers in Oncology</i> , 2021, 11, 751986.	2.8	3
29	Patients affected by squamous cell carcinoma of the head and neck: A population particularly prone to developing severe forms of COVID-19. <i>Experimental and Therapeutic Medicine</i> , 2021, 22, 1298.	1.8	1
30	Evaluation of MGMT gene methylation in neuroendocrine neoplasms. <i>Oncology Research</i> , 2021, , .	1.5	9
31	Unexpected tumor reduction in metastatic colorectal cancer patients during SARS-Cov-2 infection. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110114.	3.2	21
32	The Tumor Dynamism Is the Dark Matter of the NGS Galaxy: How to Understand It?. <i>Cancers</i> , 2021, 13, 5476.	3.7	0
33	Pre-Treatment Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Predictors of Occult Cervical Metastasis in Clinically Negative Neck Supraglottic and Glottic Cancer. <i>Journal of Personalized Medicine</i> , 2021, 11, 1252.	2.5	2
34	Intrahepatic cholangiocarcinoma and its differential diagnosis at MRI: how radiologist should assess MR features. <i>Radiologia Medica</i> , 2021, 126, 1584-1600.	7.7	48
35	Minimally invasive surgical treatment of intrahepatic cholangiocarcinoma: A systematic review. <i>World Journal of Gastrointestinal Oncology</i> , 2021, 13, 2203-2215.	2.0	13
36	Immune Response Against Head and Neck Cancer: Biological Mechanisms and Implication on Therapy. <i>Translational Oncology</i> , 2020, 13, 262-274.	3.7	49

#	ARTICLE	IF	CITATIONS
37	MGMT Promoter Methylation as a Target In Metastatic Colorectal Cancer: Rapid Turnover and Use of Folates Alter its Studyâ€™Letter. <i>Clinical Cancer Research</i> , 2020, 26, 3493-3494.	7.0	1
38	Study of Ras Mutationsâ€™™ Prognostic Value in Metastatic Colorectal Cancer: STORIA Analysis. <i>Cancers</i> , 2020, 12, 1919.	3.7	25
39	New CXCR4 Antagonist Peptide R (Pep R) Improves Standard Therapy in Colorectal Cancer. <i>Cancers</i> , 2020, 12, 1952.	3.7	16
40	Evolution of Mutational Landscape and Tumor Immune-Microenvironment in Liver Oligo-Metastatic Colorectal Cancer. <i>Cancers</i> , 2020, 12, 3073.	3.7	28
41	Effect of Octreotide Long-Acting Release on Tregs and MDSC Cells in Neuroendocrine Tumour Patients: A Pivotal Prospective Study. <i>Cancers</i> , 2020, 12, 2422.	3.7	5
42	Diffusion-Weighted MRI and Diffusion Kurtosis Imaging to Detect RAS Mutation in Colorectal Liver Metastasis. <i>Cancers</i> , 2020, 12, 2420.	3.7	42
43	Multicenter Single-Arm, Two-Stage Phase 2 Study of Panitumumab in Patients With Cetuximab-Refractory Metastatic Colorectal Cancer: The PACER Trial. <i>Clinical Colorectal Cancer</i> , 2020, 19, 270-276.	2.3	0
44	Genetic trajectory and immune microenvironment of lung-specific oligometastatic colorectal cancer. <i>Cell Death and Disease</i> , 2020, 11, 275.	6.3	21
45	Management of HPV-Related Squamous Cell Carcinoma of the Head and Neck: Pitfalls and Caveat. <i>Cancers</i> , 2020, 12, 975.	3.7	30
46	Prognostic and Predictive Role of CXC Chemokine Receptor 4 in Metastatic Colorectal Cancer Patients. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2020, 28, 755-760.	1.2	12
47	Metastatic Colorectal Cancer: Prognostic and Predictive Factors. <i>Current Medicinal Chemistry</i> , 2020, 27, 2779-2791.	2.4	4
48	Future directions and management of liquid biopsy in non-small cell lung cancer. <i>Exploration of Targeted Anti-tumor Therapy</i> , 2020, 1, 239-252.	0.8	3
49	Updates on the Role of Molecular Alterations and NOTCH Signalling in the Development of Neuroendocrine Neoplasms. <i>Journal of Clinical Medicine</i> , 2019, 8, 1277.	2.4	24
50	Safety and Activity of Metronomic Temozolomide in Second-Line Treatment of Advanced Neuroendocrine Neoplasms. <i>Journal of Clinical Medicine</i> , 2019, 8, 1224.	2.4	10
51	Folfiri-Aflibercept vs. Folfiri-Bevacizumab as Second Line Treatment of RAS Mutated Metastatic Colorectal Cancer in Real Practice. <i>Frontiers in Oncology</i> , 2019, 9, 766.	2.8	18
52	Cetuximab, irinotecan and fluorouracile in fiRst-line treatment of immunologically-selected advanced colorectal cancer patients: the CIFRA study protocol. <i>BMC Cancer</i> , 2019, 19, 899.	2.6	10
53	<p>Lenvatinib, a molecule with versatile application: from preclinical evidence to future development in anti-cancer treatment<p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 3847-3860.	1.9	78
54	Can the addition of radiotherapy postoperatively increase clinical outcome of patients with gastric cancer? A systematic review of the literature and meta-analysis. <i>Oncotarget</i> , 2018, 9, 10734-10744.	1.8	8

#	ARTICLE	IF	CITATIONS
55	Funds Reimbursement of High-Cost Drugs in Gastrointestinal Oncology: An Italian Real Practice 1 Year Experience at the National Cancer Institute of Naples. <i>Frontiers in Public Health</i> , 2018, 6, 291.	2.7	3
56	First Biologic Drug in the Treatment of RAS Wild-Type Metastatic Colorectal Cancer: Anti-EGFR or Bevacizumab? Results From a Meta-Analysis. <i>Frontiers in Pharmacology</i> , 2018, 9, 441.	3.5	9
57	Biotherapies in Solid Tumors: Are Negative Results Still of Low Priority for Publication?. <i>Frontiers in Oncology</i> , 2018, 8, 62.	2.8	2
58	Metastatic Colorectal Cancer: Role of Target Therapies and Future Perspectives. <i>Current Cancer Drug Targets</i> , 2018, 18, 421-429.	1.6	50
59	Obesity and Cancer: Biological Links and Treatment Implications. <i>Current Cancer Drug Targets</i> , 2018, 18, 231-238.	1.6	19
60	Integration of stereotactic radiotherapy in the treatment of metastatic colorectal cancer patients: a real practice study with long-term outcome and prognostic factors. <i>Oncotarget</i> , 2018, 9, 35251-35265.	1.8	6
61	Therapy for Metastatic Disease: Stomach/Duodenum, Colon/Rectum. , 2018, , 277-293.		0
62	Real practice studies in oncology: A positive perspective. <i>World Journal of Gastrointestinal Oncology</i> , 2018, 10, 228-230.	2.0	0
63	Gemcitabine mono-therapy versus gemcitabine plus targeted therapy in advanced pancreatic cancer: a meta-analysis of randomized phase III trials. <i>Acta Oncologica</i> , 2017, 56, 377-383.	1.8	46
64	FOLFOXIRI in metastatic colorectal cancer: A criticism from its native land. <i>Cancer Letters</i> , 2017, 408, 71-72.	7.2	1
65	Hyaluronic Acid Nanohydrogel Loaded With Quercetin Alone or in Combination to a Macrolide Derivative of Rapamycin RAD001 (Everolimus) as a New Treatment for Hormone-Responsive Human Breast Cancer. <i>Journal of Cellular Physiology</i> , 2017, 232, 2063-2074.	4.1	38
66	Anticancer and Anti-Inflammatory Properties of Ganoderma lucidum Extract Effects on Melanoma and Triple-Negative Breast Cancer Treatment. <i>Nutrients</i> , 2017, 9, 210.	4.1	91
67	Natural killer cells activity in a metastatic colorectal cancer patient with complete and long lasting response to therapy. <i>World Journal of Clinical Cases</i> , 2017, 5, 390.	0.8	8
68	Nab-Paclitaxel and Gemcitabine in Advanced Pancreatic Cancer: The One-year Experience of the National Cancer Institute of Naples. <i>Anticancer Research</i> , 2017, 37, 1975-1978.	1.1	7
69	Nab-paclitaxel and gemcitabine in advanced pancreatic cancer: The one-year experience of the National Cancer Institute of Naples.. <i>Journal of Clinical Oncology</i> , 2017, 35, 497-497.	1.6	1
70	CXCR4, CXCL12, CXCR7, TLR2, TLR4, and PD-1/PD-L1 in colorectal cancer liver metastases from neoadjuvant-treated patients. <i>Oncolmmunology</i> , 2016, 5, e1254313.	4.6	36
71	Diabetes and Body Mass Index Are Associated with Neuropathy and Prognosis in Colon Cancer Patients Treated with Capecitabine and Oxaliplatin Adjuvant Chemotherapy. <i>Oncology</i> , 2016, 90, 36-42.	1.9	60
72	Indications for Systemic Chemotherapy. <i>Updates in Surgery Series</i> , 2016, , 57-63.	0.1	0

#	ARTICLE	IF	CITATIONS
73	Prospective Evaluation of Cetuximab-Mediated Antibody-Dependent Cell Cytotoxicity in Metastatic Colorectal Cancer Patients Predicts Treatment Efficacy. <i>Cancer Immunology Research</i> , 2016, 4, 366-374.	3.4	61
74	Best Sequence Therapy in RAS Wild-Type Metastatic Colorectal Cancer: Waiting for Randomized Crossover Clinical Trials. <i>Journal of Clinical Oncology</i> , 2016, 34, 1563-1564.	1.6	3
75	Antiangiogenic Therapy in Pancreatic Neuroendocrine Tumors. <i>Anticancer Research</i> , 2016, 36, 5025-5030.	1.1	26
76	A clinical and radiological objective tumor response with somatostatin analogs (SSA) in well-differentiated neuroendocrine metastatic tumor of the ileum: a case report. <i>OncoTargets and Therapy</i> , 2015, 8, 669.	2.0	0
77	Effect of ranolazine administered after trastuzumab treatment on cardiotoxicity in mice.. <i>Journal of Clinical Oncology</i> , 2015, 33, 597-597.	1.6	0
78	Etanercept induces remission of polyarteritis nodosa: a case report. <i>Frontiers in Pharmacology</i> , 2014, 5, 122.	3.5	5
79	Nilotinib for the Frontline Treatment of Chronic Myeloid Leukemia Carrying the p230 Transcript: Dream or Reality?. <i>Frontiers in Oncology</i> , 2014, 4, 17.	2.8	1
80	Second-Line Chemotherapy in Recurrent Clear Cell Ovarian Cancer: Results from the Multicenter Italian Trials in Ovarian Cancer (MITO-9). <i>Oncology</i> , 2014, 86, 351-358.	1.9	20
81	Early PET/CT Scan Is More Effective Than RECIST in Predicting Outcome of Patients with Liver Metastases from Colorectal Cancer Treated with Preoperative Chemotherapy Plus Bevacizumab. <i>Journal of Nuclear Medicine</i> , 2013, 54, 2062-2069.	5.0	51
82	Prediction of response to anti-EGFR antibodies in metastatic colorectal cancer: looking beyond EGFR inhibition. <i>Frontiers in Immunology</i> , 2013, 3, 409.	4.8	0
83	High HMGA2 expression and high body mass index negatively affect the prognosis of patients with ovarian cancer. <i>Journal of Cellular Physiology</i> , 2013, 229, n/a-n/a.	4.1	32
84	Assessment of expenditure control and prescriptive appropriateness of biological drugs in autoimmune diseases and chronic inflammatory bowel disease. <i>Frontiers in Pharmacology</i> , 2013, 4, 31.	3.5	2
85	Telaprevir or boceprevir for hepatitis C treatment: a first survey on pharmacoutilization. <i>Frontiers in Pharmacology</i> , 2013, 4, 114.	3.5	6
86	Epidemiology and Economic Impact of Celiac Disease in the South Vesuvian Area of Naples: A Survey. <i>Frontiers in Public Health</i> , 2013, 1, 18.	2.7	3
87	Abstract 2393: Fc gamma receptor IIIa polymorphisms correlated with antibody-dependent cell-mediated cytotoxicity (ADCC): anti-EGFR antibodies induced and clinical outcome in metastatic colorectal cancer patients.. , 2013, , .		0
88	Early PET/CT scan compared with RECIST to predict long-term outcome of patients with liver metastases from colorectal cancer treated with preoperative chemotherapy plus bevacizumab.. <i>Journal of Clinical Oncology</i> , 2013, 31, 11008-11008.	1.6	0
89	Gastrointestinal Non Colorectal Cancer. Do Elderly Patients Need a Specific Management?. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2013, 13, 1364-1370.	1.7	0
90	Fc gamma receptor IIIa polymorphisms in advanced colorectal cancer patients correlated with response to anti-EGFR antibodies and clinical outcome. <i>Journal of Translational Medicine</i> , 2012, 10, 232.	4.4	34

#	ARTICLE	IF	CITATIONS
91	FOLFIRI plus bevacizumab (B) as neoadjuvant treatment for potentially resectable colorectal cancer patients (pts) with liver metastasis: A phase II trial.. Journal of Clinical Oncology, 2012, 30, e14130-e14130.	1.6	0
92	Surgical and Medical Treatment of Clear Cell Ovarian Cancer. International Journal of Gynecological Cancer, 2011, 21, 1063-1070.	2.5	43
93	CD4+CD45RA+CXCR4+ lymphocytes are inversely associated with progression in stages Iâ€“III melanoma patients. Cancer Immunology, Immunotherapy, 2010, 59, 511-517.	4.2	1
94	Cetuximab-dependent ADCC in cancer: dream or reality?. Cancer Immunology, Immunotherapy, 2010, 59, 1607-1608.	4.2	7
95	Finding markers for cancer stem cells in renal cell carcinoma: Looking beyond CD133. Cell Cycle, 2010, 9, 4431-4431.	2.6	15
96	CXC chemokine receptor 4 is expressed in uveal malignant melanoma and correlates with the epithelioid-mixed cell type. Cancer Immunology, Immunotherapy, 2007, 56, 1589-1595.	4.2	36
97	Overexpression of Both CXC Chemokine Receptor 4 and Vascular Endothelial Growth Factor Proteins Predicts Early Distant Relapse in Stage II-III Colorectal Cancer Patients. Clinical Cancer Research, 2006, 12, 2795-2803.	7.0	158
98	Human Melanoma Metastases Express Functional CXCR4. Clinical Cancer Research, 2006, 12, 2427-2433.	7.0	114
99	Evidence of publication bias in clinical trials of biotherapies for solid tumors. Cancer, 2005, 103, 653-653.	4.1	5
100	Prospective clinical trials of biotherapies in solid tumors: a 5-year survey. Cancer Immunology, Immunotherapy, 2005, 54, 44-50.	4.2	12
101	Inhibitory effects of anti-CXCR4 antibodies on human colon cancer cells. Cancer Immunology, Immunotherapy, 2005, 54, 781-791.	4.2	78
102	Expression of CXCR4 Predicts Poor Prognosis in Patients with Malignant Melanoma. Clinical Cancer Research, 2005, 11, 1835-1841.	7.0	260
103	Biological prognostic factors in adult soft tissue sarcomas. Anticancer Research, 2005, 25, 4519-26.	1.1	25
104	Prognostic Value of CD40 in Adult Soft Tissue Sarcomas. Clinical Cancer Research, 2004, 10, 2824-2831.	7.0	12
105	Statistical design in phase II clinical trials and its application in breast cancer. Lancet Oncology, The, 2003, 4, 305-311.	10.7	25
106	CD40 activation as potential tool in malignant neoplasms. Tumori, 2002, 88, 361-6.	1.1	13
107	Pancreatic involvement from heavily pretreated small cell lung cancer successfully treated with transcatheter intra-arterial chemotherapy: a case report with local and systemic disease control. Tumori, 2002, 88, 535-7.	1.1	1